PharmAthene v. Siga [Premium]

CONCLUDED

Trial
01/03/11 – 01/21/11

Play button overlay 45f08f27c7337d189e8c31e635b5d0a0781b273131135cd77ee8b6f12366e7a2
Play button overlay 45f08f27c7337d189e8c31e635b5d0a0781b273131135cd77ee8b6f12366e7a2

Summary

Post-trial oral arguments scheduled for April 29, 2011.

In this Pharmaceutical mergers and acquisition litgation proceeding, Plaintiff PharmAthene alleged Siga Technologies of breaching its obligations to negotiate in good faith a definitive license agreement in accordance with the terms of license agreement term sheet it signed for the development of a small pox drug with the plaintiff.

The plaintiff was represented by attorney Roger Crane. The defendant in this case, Siga Technologies was represented by attorneys Harold Weinberger.


For more information, visit the CVN News Blog.

Outcome

The court found that SGIA was liable for the breach of contractual obligations to negotiate a license agreement in good faith and promissory estoppel. Judgment was entered for an equitable payment stream or equitable lien on the profits or the other qualifying proceeds associated with commercial sale of ST-246 or products that were derived from it Also, PharmAthene was awarded one-third of its attorneysÂ’ fees, expert witness costs, and other costs.

Sessions

Recording Disclaimer: This proceeding was recorded in full except noted sections that were not recorded.

Suggest a Trial

Want to see a trial that you don't see in our list of upcoming trials?

Suggest a Case

CVN Essentials

The most important and informative moments of each trial

CVN Essentials

Video Library

Unlimited access to thousands of hours of past coverage of high stakes civil litigation

Video Library

  • Follow Us
  • Contact Us
  • 3901 Roswell Road
  • Suite 302
  • Marietta, GA 30062
  • 877-838-9067

Copyright 2019 Courtroom Connect.